Loading...
The URL can be used to link to this page
Your browser does not support the video tag.
Home
My WebLink
About
071923 You're helping our scientists make breakthroughs
________________________________ ALERT: BE CAUTIOUS This email originated outside the organization. Do not open attachments or click on links if you are not expecting them. ________________________________ Recent advances show how your support fuels discovery. We can do more with your help. Give Now <https://secure.fredhutch.org/site/R?i=tBeIrkRYvm7T9lCHoaFX5RtKeiponb-5NRF7B-UXdCjXKQYK3FPhoA> . <https://secure.fredhutch.org/site/R?i=TLBAts-JDATLIHemkOIGtouNrCS1kfl_olHPl7zf7b9FkKeRnz7_ew> Support Leading-Edge Science <https://secure.fredhutch.org/site/R?i=egNnX9JlBFSFzWsCN9qnQyIjzRQ7Dv2Zl7E-nCgH8u_UYXUtvhsFTQ> A class of drugs known as immune checkpoint inhibitors has greatly extended the lives of patients with advanced cancers. For example, patients with advanced melanoma now survive for an average of five years. The average used to be nine months. The problem is that treating patients with standard doses of immune checkpoint inhibitors for an indefinite period of time is extremely expensive and requires patients to spend long hours traveling and in clinics. Shailender Bhatia, MD, and Lisa Tachiki, MD, at Fred Hutchinson Cancer Center and UW Medicine, may have a solution. They offered patients in their clinic the option to be part of studying a new approach to treatment called reduced‑frequency dosing. 23 patients enrolled. These patients received infusions of immune checkpoint inhibitors every two to three months, instead of every two to four weeks. When the results were in, they showed that survival for patients who received reduced-frequency dosing was comparable to survival for those who followed the standard dosing schedule. Reduced-frequency dosing also saved $1.1 million in drug costs and saved patients a combined total of 384 hours they would otherwise have spent in clinics or traveling to appointments. If additional research confirms reduced-frequency dosing is an effective treatment alternative, the impact could be enormous — especially for patients who otherwise would not have access to immune checkpoint inhibitors at all. Your support <https://secure.fredhutch.org/site/R?i=XTal6bA0RqMYaY_OhznZEgSXhYwk5FPxy9XnTcFExLNu_ygo5ZNoNA> is an important part of making research like this possible. <https://secure.fredhutch.org/site/R?i=AHJfh3eBVbjTi29J6NhiQQMqdUcO1LAtbSyx9lsgyrvwTA_j70h8Aw> Fred Hutchinson Cancer Center is an independent organization that serves as UW Medicine’s cancer program. <https://secure2.convio.net/fhcrc/images/content/pagebuilder/October_Cure_Cancer_Faster_Email_1_UW_logo_v2.png> <https://secure.fredhutch.org/site/R?i=H7yT2gH1IoICzePBMHFAytfJZXJsPVry1f31QZJOlDSH4657WdXw6w> <https://secure.fredhutch.org/site/R?i=aZm2wzdULY-hGjNE7Xsxba_siyjan7rrXr7eRhnL4B3LbM8p8cHDTQ> <https://secure.fredhutch.org/site/R?i=nAJoU7Ad1liGdjIbP4YR01pvhJX4CEzSBWNuVEPQWgNZQSU02P9_lQ> <https://secure.fredhutch.org/site/R?i=MsNDJTi7T-VvDjCkOvf4XRuxHOtr0yBLjOuClHRNfgwWAN_TsS-0tw> <https://secure.fredhutch.org/site/R?i=BCVE54zpHAZqa_N6U8VKmQLXRrmWH4mqfmLQ0F5m_v-EZoXZhqx3kQ> 1100 Fairview Ave. N, Mail Stop J5-200, Seattle, WA 98109 annualgiving@fredhutch.org <mailto:annualgiving@fredhutch.org> 206.667.4399 <https://secure.fredhutch.org/site/R?i=hNwQlt8DxRec-xJ0KY1VPIbWkQNazZgirRa0eDzfvQ5LR_6B7bMQYg> <https://secure.fredhutch.org/site/R?i=vN1Dt-_rk34VzatbcROhC0oAOOKh-ykRbEg1larS4cbrOfVhJ9uokQ> <https://secure.fredhutch.org/site/R?i=312sd27BbQzOqng_KnZkuYD1IBT1Vila44op8f56N67KaptgtHu3iA> <https://secure.fredhutch.org/site/R?i=JAODAb5j2A8WYx-i9Sf20oBQSlFvmhyNIDkFc6BvM-61zinF1b0YEQ> <https://secure.fredhutch.org/site/R?i=jcGkzdpuGaDpdmuUGLlzzY5xlckKotFBPP5z-5E8Pg0I5mih_OCxnA> Fred Hutchinson Cancer Center is a 501(c)(3) nonprofit organization. Unsubscribe <http://engage.fredhutch.org/site/CO?i=BEaQlOq93YyyU7wfhFp5Nf9l0u1DVwQpXbpLuGalbJk739MR9tpP8XSKgNpriwJO&cid=0> from Fred Hutch emails or contact us at optout@fredhutch.org <mailto:optout@fredhutch.org> to be removed from our mailing list. For information about our privacy practices, see our Privacy Policy <https://secure.fredhutch.org/site/R?i=gdxXXyc7iPhICyYCX0KonHgRCxyFY0D2LWtIf3l6KCzdbnHs0xA9lA> . © 2023 Fred Hutchinson Cancer Center. All rights reserved. <http://engage.fredhutch.org/site/PixelServer?j=sKWNZJp4OOfcjf4yJtEeRpD4e4Sbv2iJLgnNT4L-txp1Ea5wrjoV7Q>